Journey Medical (DERM) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Journey Medical (DERM) has outperformed Upstream Bio (UPB) over the past year, losing 31.0% versus a loss of 86.8%. Upstream Bio is the larger company by market cap ($151.2 million vs $140.1 million), about 1.1 times the size. Journey Medical converts more of its revenue into profit, with a net margin of -18.5% versus -5026.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DERM | UPB |
|---|---|---|
| Share price | $4.97 | $2.76 |
| Market cap | $140.13M | $151.17M |
| 1-day change | -3.12% | -18.10% |
| YTD return | -35.60% | -89.83% |
| 1-year return | -31.04% | -86.84% |
| EPS (TTM) | $-0.22 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $61.86M | $2.85M |
| Revenue growth (YoY) | +10.20% | +20.42% |
| Net income (latest FY) | $-11.43M | $-143.44M |
| Gross margin | 66.17% | — |
| Operating margin | -13.21% | -5618.82% |
| Net margin | -18.48% | -5026.03% |
| 52-week high | $9.56 | $33.68 |
| 52-week low | $4.31 | $2.74 |
| Distance from 52-week high | -48.04% | -91.81% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +176.94% | +1028.26% |
| Average volume | 189.75K | 734.05K |
| Shares outstanding | 22.22M | 54.77M |
| Employees | 58 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DERM has outperformed UPB by 55.8 percentage points over the past year.
- Journey Medical is more profitable, keeping -18.5 cents of every revenue dollar as net income versus -5026.0 cents for Upstream Bio.
- Upstream Bio grew revenue faster in its latest fiscal year (+20.42% vs +10.20%).
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
DERM vs UPB FAQ
Which is bigger, Journey Medical or Upstream Bio?
Upstream Bio (UPB) is larger, with a market capitalization of $151.17M compared with $140.13M for Journey Medical (DERM).
Which stock has performed better over the past year, DERM or UPB?
DERM returned -31.04% over the past 12 months, compared with -86.84% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Journey Medical and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.